Literature DB >> 6603166

Pharmacologic actions of 4-aminoquinoline compounds.

A H Mackenzie.   

Abstract

The pharmacokinetics, physiologic effects, and the metabolization of chloroquine and hydroxychloroquine are all similar. Their concentrations in plasma and tissue are directly related to daily dosing. The highest concentrations are found in melanin-containing tissues, particularly the choroid and ciliary body of the eye. The pharmacologic effects of 4-aminoquinoline compounds are reviewed in detail. It is likely that the rheumatologic effectiveness of these agents is primarily related to lysosomal actions. The drug-induced lysosomal abnormalities include diminished vesicle fusion, diminished exocytosis, and reversible "lysosomal storage disease." It is likely that the retinal toxicity of these drugs is one manifestation of the altered lysosomal physiology involving the retinal pigmented epithelium. Tissue of retinal pigmented epithelium is similar to that of the bone-marrow-derived macrophage. Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines. Dosages ranging from 3.5 to 4.0 mg/kg per day for chloroquine and 6.0 to 6.5 mg/kg per day for hydroxychloroquine are clinically safe.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603166     DOI: 10.1016/0002-9343(83)91264-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leucocyte superoxide production by chloroquine and hydroxychloroquine.

Authors:  N P Hurst; J K French; L Gorjatschko; W H Betts
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

2.  Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells.

Authors:  Jae-Yeon Jeong; Jae Won Choi; Kye-Im Jeon; Dae-Myung Jue
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

3.  Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.

Authors:  S M Levitz; T S Harrison; A Tabuni; X Liu
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens.

Authors:  T F Byrd; M A Horwitz
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy.

Authors:  J K French; N P Hurst; M L O'Donnell; W H Betts
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

6.  Increased autophagy contributes to the inflammatory phenotype of juvenile idiopathic arthritis synovial fluid T cells.

Authors:  Janneke G C Peeters; Nienke de Graeff; Martin Lotz; Salvatore Albani; Sytze de Roock; Jorg van Loosdregt
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

7.  Differential uptake of chloroquine by human keratinocytes and melanocytes in culture.

Authors:  G Sjölin-Forsberg; B Berne; M Johansson; M J Olsson; O Rollman
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

Review 8.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

9.  Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

Authors:  R B Landewé; A M Miltenburg; M J Verdonk; C L Verweij; F C Breedveld; M R Daha; B A Dijkmans
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

10.  Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis.

Authors:  S L Newman; L Gootee; G Brunner; G S Deepe
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.